story of the week
Abiraterone Acetate and Prednisolone ± Enzalutamide in High-Risk Nonmetastatic Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Lancet 2021 Dec 23;[EPub Ahead of Print], G Attard, L Murphy, NW Clarke, W Cross, RJ Jones, CC Parker, S Gillessen, A Cook, C Brawley, CL Amos, N Atako, C Pugh, M Buckner, S Chowdhury, Z Malik, JM Russell, C Gilson, H Rush, J Bowen, A Lydon, I Pedley, JM O'Sullivan, A Birtle, J Gale, N Srihari, C Thomas, J Tanguay, J Wagstaff, P Das, E Gray, M Alzoueb, O Parikh, A Robinson, I Syndikus, J Wylie, A Zarkar, G Thalmann, JS de Bono, DP Dearnaley, MD Mason, D Gilbert, RE Langley, R Millman, D Matheson, MR Sydes, LC Brown, MKB Parmar, ND JamesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.